Shailendra Singh is an experienced life science research scientist with over 18 years’ academic and commercial experience in diagnostic, pharmaceutical and biotech/biomedical sectors.
Originally qualifying as a medical doctor specializing in immunology, he then went on to train as a Pathologist and Immunologist. This led to his appointment as a Laboratory Operations Manager for Thyrocare Technologies Ltd., one of the leading Diagnostic Laboratory in India. He then went on to complete his Master of Research and PhD in Molecular Medicine from University of Nottingham, UK.
Stuart Gibson is an experienced CFO who since 2001 has focused on early stage biotech and technology companies. In 2001 he joined Arakis Ltd and was involved in raising £49M of venture capital, a worldwide licencing deal with Novartis for COPD treatment (AD237/QVA149 – now both approved treatments on the market) and the subsequent sale of Arakis to the Japanese quoted pharma company Sosei for £106M in 2006.
Stuart was appointed as the EVP of Finance in Sosei shortly after and raised further funding on the Tokyo stock market before leaving in 2008. From 2008 to 2015 worked for ARKeX a new technology company operating worldwide in the Oil & Gas services sector. During his tenure he raised over £40M of capital in equity & debt instruments, and was involved in contract negotiations with customers and business partners globally including North Africa, Middle East and China.
David Lambert trained as a Biologist then did PhD in Diabetes Research (1987). This was followed by Post-doctoral ‘conversion’ to Pharmacology in Leicester, after which he then moved to Anaesthesia Dept in Leicester in 1991 where he has since been Lecturer, Senior Lecturer, Reader and Full Professor.
His anaesthetic research interests are predominantly related to peptides and their receptors with emphasis on opioids/pain, cannabinoids and anaesthesia and lately the cardiovascular peptide urotensin II. He has ~250 publications (excluding abstracts) with h-index 35. Publications include book in 3rd edition and one patent.
Anushuya holds a PhD in Developmental Biology and Embryology, and M.Res in Cancer Biology from Nottingham Trent University, UK. Her PhD research focused on “The differential expression of Cancer Testis Antigens and 5-HT Receptors in Normotensive and Pre-eclamptic Placentae, and their role in trophoblast invasion”.
During her PhD, she also worked as part-time Lecturer for Pharmacology and Bioscience Department at Nottingham Trent University.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.